- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Jonathan Sweeting on Aybintio's European Approval
We sat down with Jonathan Sweeting, head of Samsung Bioepis’ European business, to discuss the steps leading up to the European approval of Aybintio and what the current bevacizumab market in Europe looks like.
In August, Samsung Bioepis, a biopharmaceutical manufacturer based in the Republic of Korea, received European Commission (EC) marketing authorization for its bevacizumab biosimilar, Aybintio.
The EC approved Aybintio for all indications of the reference product, Avastin, including colorectal, breast, and lung cancer. Although Aybintio will increase price competition in Europe, how the individual biosimilar will fare against its already established competitors remains to be seen.
We sat down with Jonathan Sweeting, head of Samsung Bioepis’ European business, to discuss the steps leading up to the approval of Aybintio and what the current bevacizumab market in Europe looks like.
To learn more about the EC's approval of Aybintio, click here.
To learn more about Samsung Bioepis, click here.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
